Accurate and early response assessment is essential for personalized medicine not only to optimize systemic therapy for metastasized disease but also to tailor local treatment after neoadjuvant chemoradiotherapy. Both can be a daily conundrum leading to challenging clinical questions. The assessment of the efficacy of the current treatment or the resectability after local therapy often requires multimodal imaging expertise, as well as a profound understanding of the therapeutic mechanism.
Copyright 2018, The Author(s).